Technical aspects and intraoperative factors influencing the efficiency of non-penetrating deep sclerectomy and implantation of PreserFlo MicroShunt Review article

Main Article Content

Patrycja Soja
Piotr Jurowski

Abstract

Glaucoma is a neurodegenerative disorder marked by the death of retinal ganglion cells which causes characteristic vision field loss. At the moment the only well-known risk factor for progression of the glaucoma is intraocular pressure. In this regard the lowering of intraocular pressure became the main focus of treatment.


Different types of glaucoma surgeries have developed over the last decades. Most of them facilitate outflow of aqueous humor, few decrease the production. This article takes into account two of them: non-penetrating deep sclerectomy and implantation of PreserFlo MicroShunt.


Deep sclerectomy is a well established non-penetrating type of glaucoma surgery. With use of adjuvant methods such as use of space-maintaining implants, use of viscoelastic agent and use of antimetabolites during procedure it allowed to achieve success rate of standard penetrating surgery with lower rate of complications.


PreserFlo MicroShunt implantation is a promising new filtration procedure for glaucoma treatment. First published studies show promising efficacy and safety outcomes, although further research is needed.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Soja P, Jurowski P. Technical aspects and intraoperative factors influencing the efficiency of non-penetrating deep sclerectomy and implantation of PreserFlo MicroShunt. Ophthatherapy [Internet]. 2023Dec.31 [cited 2024Jun.19];10(4):304-9. Available from: https://www.journalsmededu.pl/index.php/ophthatherapy/article/view/2945
Section
Surgery and laser therapy

References

1. Varga Z, Shaarawy T. Deep sclerectomy: safety and efficacy. Middle East Afr J Ophthalmol. 2009; 16(3): 123-6. http://doi.org/10.4103/0974-9233.56223.
2. Kozobolis VP, Christodoulakis EV, Tzanakis N et al. Primary deep sclerectomy versus primary deep sclerectomy with the use of mitomycin C in primary open-angle glaucoma. J Glaucoma. 2002; 11(4): 287-93. http://doi.org/10.1097/00061198-200208000-00003.
3. Sanchez E, Schnyder CC, Sickenberg M et al. Deep sclerectomy: results with and without collagen implant. Int Ophthalmol. 1996; 20(1-3): 157-62. http://doi.org/10.1007/BF00212963.
4. Shaarawy T, Mermoud A. Deep sclerectomy in one eye vs deep sclerectomy with collagen implant in the contralateral eye of the same patient: long-term follow-up. Eye (Lond). 2005; 19(3): 298-302. http://doi.org/10.1038/sj.eye.6701469.
5. Oana S, Vila A, Suriano M et al. A New Implant for Deep Sclerectomy: Esnoper®. J Curr Glaucoma Pract. 2011; 5(3): 40-3. http://doi.org/10.5005/jp-journals-10008-109.
6. Strickler F, Richard R, McFadden S et al. In vivo and in vitro characterization of poly(styrene-b-isobutylene-b-styrene) copolymer stent coatings for biostability, vascular compatibility and mechanical integrity. J Biomed Mater Res A. 2010; 92(2): 773-82. http://doi.org/10.1002/jbm.a.32418.